1/5 Practice-changing at #ASCO26: the PREPEC trial (OPBC-02), presented by Walter Weber — the first international phase III RCT comparing pre- vs sub-pectoral implant breast reconstruction . 383 pts, 26 centers, 10 countries. #bcsm
We took advantage of being together at #ASCO2026 for a meeting of the Lancet Commission on Cancer and Health Systems. Great to connect in person and advance our shared work! We missed our colleagues Mary Gospodarowicz, C.S. Pramesh, Patricia Garcia and Bev Essue. Looking forward to the full team being together soon.
Tuvimos la oportunidad de reunirnos con miembros de la Comisión Lancet sobre Cáncer y Sistemas de Salud durante #ASCO2026. ¡Fue un gusto conectar en persona y seguir avanzando en nuestro trabajo conjunto! Extrañamos a nuestros colegas Mary Gospodarowicz, C.S. Pramesh, Patricia Garcia y Bev Essue, y esperamos que todo el equipo pueda reunirse pronto.
#ASCO2026 #LancetCommission #HealthSystems #GlobalHealth #UHC #HealthEquity @TheLancet@WisdomVania@jrgralow@renu_nargund@andrepfob@Dilyara_Kaidar@lsaulsbe@mtkutluk
📌 Lymph node surgery and CDK4/6 inhibitors in early breast cancer: A cost-consequence analysis from 5 randomized trials
✨Rapid Oral Session 1
@andrepfob#ESMOBreast26@OncoAlert#OncoAlertAF
🔗 https://t.co/6LTIFNwtvg
At #EBCC15, the first ED session explored how AI is already shaping breast cancer care and what still needs to be addressed. From screening to research, AI shows real impact. But one message stood out:
“AI is only as good as the data behind it.” Human oversight remains essential.
🎧Listen to our Dec podcast with @breastDoktor and @andrepfob discussing the Lucerne Toolbox 3 (📑https://t.co/gOsH7QSSit), digital health and AI in early breast cancer
Spotify: https://t.co/ODNEz8V87P
Apple: https://t.co/0B0UdUOYli
AI-guided shear wave elastography model showed similar accuracy to expert readings of B-mode ultrasound for diagnosis of BI-RADS 3/4 masses #BreastCancer
🔸 Significantly reduced false positives (20.4% vs 53.8%; P < .001)
From Lie Cai, MD; @DrGolatta
https://t.co/ID3yeirCly
Deep Learning Model for Breast Shear Wave Elastography to Improve #BreastCancer Diagnosis (INSPiRED 006)
https://t.co/ztrp8KEbYH
This international, multicenter study evaluated a deep learning model trained on shear wave elastography (SWE) images (AI-SWE) to improve diagnosis of BI-RADS 3 and 4 breast masses. Using data from over 1,200 patients across 12 sites, the model achieved high accuracy (AUROC ~0.93–0.94) in two external validation cohorts, including data from newer SWE software. Compared with B-mode ultrasound alone, AI-SWE maintained equivalent sensitivity (~98%) but reduced false positives by up to 62%, suggesting a potential role in lowering unnecessary biopsies.
These findings support AI-SWE as a promising tool to complement breast cancer diagnostics, warranting further integration into clinical workflows.
@OncoAlert 🚨
@liecaii@andrepfob@drcgibbons@DrGolatta
Do All Early-stage Breast Cancer Patients Need Axillary Staging?
Melissa Pilewskie and Peter Dubsky will debate this question in a special session at #SABCS25 (December 9-12). Learn more:
https://t.co/sQsYeB7ocV
@breastDoktor
Imagine you could have a validated test that can identify patients with very low DR rates in a high-risk, MonarchE type of population. Free access to this incredible biomarker work led bei Curie and IGR ! #bcsm Journal of Clinical Oncology https://t.co/DFvdaokmQo
6/ What’s new with AI-SWE?
✔️ Evaluates the whole lesion, not just a cutoff.
✔️ Maintains sensitivity (~98%).
✔️ Cuts false positives (38–62%).
✔️ Works across multiple centers & software versions.
From Breast Center Heidelberg to the world 🌍
Deep Learning Model for Breast Shear Wave Elastography to Improve #BreastCancer Diagnosis (INSPiRED 006): An International, Multicenter Analysis. Co-authored by @andrepfob, @liecaii, @drcgibbons, et al.
Read the full article. https://t.co/53c8kajKzn
#bcsm